The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC).
A. P. Kotsakis
No relevant relationships to disclose
S. S. Ramalingam
Consultant or Advisory Role - ImClone Systems; Lilly
A. A. Tarhini
No relevant relationships to disclose
D. E. Heron
No relevant relationships to disclose
R. Smith
No relevant relationships to disclose
D. Friedland
No relevant relationships to disclose
D. P. Petro
No relevant relationships to disclose
L. E. Raez
Honoraria - ImClone Systems; Lilly
Research Funding - ImClone Systems; Lilly
J. R. Brahmer
No relevant relationships to disclose
J. S. Greenberger
No relevant relationships to disclose
S. Dacic
No relevant relationships to disclose
P. Hershberger
No relevant relationships to disclose
R. J. Landreneau
No relevant relationships to disclose
C. P. Belani
No relevant relationships to disclose
J. D. Luketich
No relevant relationships to disclose
A. Argiris
Research Funding - Bristol-Myers Squibb